Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Palisade Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 3 filings
- 1 insider, $250.2K in total
- Open-market sells
- 2 filings
- 2 insiders, $409.9K in total
- Insiders trading
- 3
- Net value
- −$159.7K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Palisade Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Finley John David | CEO, CFO | 88,451Indirect | Aug 21, 2026 | 5 |
| Baltera Robert Jr. | Director | 461,904 | Jul 10, 2026 | 4 |
| Jones Mitchell Lawrence | Chief Medical Officer | 94,009 | Jul 8, 2026 | 4 |
| Williams Donald Allen | Director | 1,570,294 | Jun 12, 2026 | 4 |
| Wei Binxian | Director | 613,355 | Jun 12, 2026 | 2 |
| Chuang Emil | Director | 612,500 | Jun 12, 2026 | 2 |
| Zwick Jordan Michael | Director | 336,904 | Jun 12, 2026 | 1 |
| Fischbein Margery B. | Director | – | Jul 15, 2024 | 0 |
| Csimma Cristina | Director | 12,862 | Feb 13, 2024 | 0 |
| Neal James R | Director | 10,920 | Feb 13, 2024 | 0 |
| Trenschel Robert J. | Director | 10,920 | Feb 13, 2024 | 0 |
| Diaz Stephanie | Director | 12,800 | Feb 13, 2024 | 0 |
| Gray Mary Ann | Director | – | Nov 24, 2023 | 0 |
| McRae Robert Curtis | Chief Operating Officer | 625 | Apr 5, 2023 | 0 |
| Hallam Thomas | Chief Executive Officer | 57,592 | Aug 18, 2022 | 0 |
| Dawson Michael John | Chief Medical Officer | 15,000 | Mar 31, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 (view filing)6:14 PM ET | Jul 8-9 | 2 days | Baltera Robert Jr.Director | PPurchase | +45.0K | $1.97 | +$88.7K | +10.8%461.9K after | 2 lots |
| Jul 8, 2026 (view filing)6:56 PM ET | Jul 6-7 | 2 days | Baltera Robert Jr.Director | PPurchase | +50.0K | $2.04 | +$102.1K | +13.6%416.9K after | 2 lots |
| Jul 8, 2026 (view filing)6:52 PM ET | Jul 7 | 1 day | Jones Mitchell LawrenceChief Medical Officer | SSale | −51.9K | $2.05 | −$106.5K | −35.6%94.0K after | |
| Jul 8, 2026 (view filing)6:49 PM ET | Jul 7 | 1 day | Finley John DavidCEO, CFO | SSale | −146.8K | $2.07 | −$303.3K | −40.3%217.6K after | |
| Jul 6, 2026 (view filing)7:48 PM ET | Jul 1-2 | 5 days | Baltera Robert Jr.Director | PPurchase | +30.0K | $1.98 | +$59.4K | +8.9%366.9K after | 2 lots |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Jones Mitchell LawrenceChief Medical Officer | SSale | −1.99K | $1.75 | −$3.48K | −13.0%13.3K after | |
| Feb 13, 2026 (view filing) | Feb 12 | 1 day | Finley John DavidCEO, CFO | SSale | −3.90K | $1.75 | −$6.82K | −12.5%27.4K after | |
| Jan 21, 2026 (view filing) | Jan 16 | 5 days | Williams Donald AllenDirector | PPurchase | +5.00K | $1.67 | +$8.35K | +87.3%10.7K after | |
| Jan 13, 2026 (view filing) | Jan 9 | 4 days | Williams Donald AllenDirector | PPurchase | +5.00K | $1.88 | +$9.40K | +686.8%5.73K after | |
| May 29, 2024 (view filing) | May 28 | 1 day | Williams Donald AllenDirector | PPurchaseComon Stock, par value $0.01 | +1.00K | $4.86 | +$4.86K | New position1.00K after | |
| May 28, 2024 (view filing) | May 24 | 4 days | Finley John DavidCEO, CFO, Director | PPurchaseCommon Stock, par value $0.01 | +1.00K | $4.81 | +$4.81K | +13.4%8.44K after | |
| Feb 7, 2024 (view filing)8:30 AM ET | Feb 6 | 1 day | Finley John DavidCEO, CFO, Director | PPurchaseCommon Stock, par value $0.01 | +10.0K | $0.4692 | +$4.69K | +13.4%84.6K after | |
| Feb 1, 2024 (view filing) | Jan 31 | 1 day | Finley John DavidCEO, CFO, Director | PPurchaseCommon Stock, par value $0.01 | +10.0K | $0.56 | +$5.60K | +15.5%74.6K after | |
| Feb 1, 2024 (view filing) | Jan 31 | 1 day | Williams Donald AllenDirector | PPurchaseCommon Stock, par value $0.01 | +10.0K | $0.61 | +$6.10K | +50.0%30.0K after | |
| Sep 29, 2023 (view filing) | Sep 27 | 2 days | Williams Donald AllenDirector | PPurchaseCommon Stock, par value $0.01 | +20.0K | $0.54 | +$10.8K | New position20.0K after | |
| Sep 29, 2023 (view filing) | Sep 27 | 2 days | Finley John DavidCEO, CFO, Director | PPurchaseCommon Stock, par value $0.01 | +15.0K | $0.54 | +$8.10K | +52.8%43.4K after | |
| Sep 15, 2023 (view filing) | Sep 14 | 1 day | Trenschel Robert J.Director | SSaleCommon Stock, par value $0.01 | −300 | $0.64 | −$192 | −100.0%0 after | |
| Sep 14, 2023 (view filing) | Sep 13 | 1 day | Finley John DavidCEO, CFO, Director | PPurchaseCommon Stock, par value $0.01 | +15.0K | $0.66 | +$9.90K | +112.0%28.4K after | |
| Sep 2, 2022 (view filing)6:21 PM ET | Sep 1 | 1 day | Finley John DavidChief Financial Officer | PPurchaseCommon Stock, par value $0.01 | +19.5K | $0.1437 | +$2.80K | +15.1%148.7K after | |
| Aug 25, 2022 (view filing)5:10 PM ET | Aug 23 | 2 days | Finley John DavidChief Financial Officer | PPurchaseCommon Stock, par value $0.01 | +7.35K | $0.16 | +$1.18K | +6.0%129.2K after | |
| Aug 18, 2022 (view filing)9:06 PM ET | Aug 16 | 2 days | Hallam ThomasChief Executive Officer | PPurchaseCommon Stock, par value $0.01 | +40.0K | $0.25 | +$10.0K | +227.4%57.6K after | |
| Aug 18, 2022 (view filing)9:06 PM ET | Aug 16 | 2 days | Hallam ThomasChief Executive Officer | PPurchase | +80.0K | $0.00 | $0 | –40.0K after | Derivative2 lots |
| Aug 18, 2022 (view filing)9:04 PM ET | Aug 16 | 2 days | Finley John DavidChief Financial Officer | PPurchaseCommon Stock, par value $0.01 | +100.0K | $0.25 | +$25.0K | +456.7%121.9K after | |
| Aug 18, 2022 (view filing)9:04 PM ET | Aug 16 | 2 days | Finley John DavidChief Financial Officer | PPurchase | +200.0K | $0.00 | $0 | –100.0K after | Derivative2 lots |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Dawson Michael JohnChief Medical Officer | PPurchase | +15.0K | $1.14 | +$17.1K | New position15.0K after | |
| Mar 29, 2022 (view filing) | Mar 28 | 1 day | Hallam ThomasChief Executive Officer | PPurchase | +10.0K | $1.18 | +$11.8K | +131.7%17.6K after | |
| Mar 25, 2022 (view filing) | Mar 24 | 1 day | Finley John DavidChief Financial Officer | PPurchase | +7.50K | $1.09 | +$8.18K | +52.1%21.9K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Finley John DavidChief Financial Officer | PPurchase | +2.00K | $2.44 | +$4.88K | +16.1%14.4K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Hallam ThomasChief Executive Officer | PPurchase | +6.00K | $2.49 | +$14.9K | +376.9%7.59K after | |
| Sep 13, 2021 (view filing) | Aug 31-Sep 10 | 13 daysLate | Trenschel Robert J.Director | PPurchase | +15.0K | $2.82 | +$42.3K | New position15.0K after | 5 lots |
| Aug 30, 2021 (view filing) | Aug 27 | 3 days | Finley John DavidChief Financial Officer | PPurchase | +10.0K | $2.65 | +$26.5K | +417.4%12.4K after | 2 lots |